Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BGG492A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BGG492 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BGG492A | DRUG | - |
Inclusion Criteria: * Patients diagnosed with THI (Tinnitus Handicap Inventory) severity grade 3, 4 or 5 (moderate, severe or catastrophic), chronic (\> 6 months and \< 36 months) subjective tinnitus * Willing to abstain from activities that require focused attention, e.g. driving a car or other ve...
BGG492A is an investigational small molecule being studied for the treatment of chronic subjective tinnitus, a condition characterized by persistent ringing or noise in the ears without an external source. It is in Phase 2 clinical development and has not been approved by regulatory authorities.
The molecular target of BGG492A has not been disclosed in available information. It is a small molecule being developed by Novartis AG for chronic subjective tinnitus, but its specific mechanism of action is not publicly detailed.
BGG492A is being developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 2 clinical trials for chronic subjective tinnitus.
BGG492A is in Phase 2 clinical development. It has completed one Phase 2 trial, and it remains an investigational drug that has not received approval from the U.S. Food and Drug Administration or other regulatory agencies.
BGG492A has been studied in one completed Phase 2 clinical trial with the identifier NCT01302873. This randomized, double-blind, placebo-controlled trial enrolled 96 participants with chronic subjective tinnitus and was conducted at sites in Germany and the Netherlands.
BGG492A is the drug name used in clinical trial records, and it may also be referred to as BGG492 in some contexts. The completed Phase 2 study NCT01302873 lists the intervention as BGG492, indicating these names refer to the same investigational compound.